{
    "Clinical Trial ID": "NCT01451632",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Part 1: Cohort 1",
        "  MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW",
        "INTERVENTION 2: ",
        "  Part 1: Cohort 2a",
        "  MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  No standard options remaining",
        "  Adequate liver and kidney functions",
        "  18 years of age or above",
        "Exclusion Criteria:",
        "  History of any secondary active cancer in the last 3 years.",
        "  Pregnant or breast feeding",
        "  History of severe allergic reactions or contraindications to cetuximab or irinotecan"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination",
        "  To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.",
        "  Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks",
        "Results 1: ",
        "  Arm/Group Title: Part 1: Cohort 1",
        "  Arm/Group Description: MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW",
        "  Overall Number of Participants Analyzed: 8",
        "  Measure Type: Number",
        "  Unit of Measure: participants reporting DLTs  1",
        "Results 2: ",
        "  Arm/Group Title: Part 1: Cohort 2a",
        "  Arm/Group Description: MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW",
        "  Overall Number of Participants Analyzed: 4",
        "  Measure Type: Number",
        "  Unit of Measure: participants reporting DLTs  0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 15/34 (44.12%)",
        "  Neutropenia * 0/34 (0.00%)",
        "  Pericardial effusion * 1/34 (2.94%)",
        "  Supraventricular tachycardia * 1/34 (2.94%)",
        "  Cardiac Arrest * 0/34 (0.00%)",
        "  Abdominal Pain * 1/34 (2.94%)",
        "  Constipation * 1/34 (2.94%)",
        "  Diarrhea * 1/34 (2.94%)",
        "  Intestinal Obstruction * 0/34 (0.00%)",
        "  Nausea * 0/34 (0.00%)",
        "  Stomatitis * 0/34 (0.00%)",
        "  Vomiting * 0/34 (0.00%)",
        "Adverse Events 2:",
        "  Total: 6/14 (42.86%)",
        "  Neutropenia * 1/14 (7.14%)",
        "  Pericardial effusion * 1/14 (7.14%)",
        "  Supraventricular tachycardia * 0/14 (0.00%)",
        "  Cardiac Arrest * 1/14 (7.14%)",
        "  Abdominal Pain * 0/14 (0.00%)",
        "  Constipation * 0/14 (0.00%)",
        "  Diarrhea * 2/14 (14.29%)",
        "  Intestinal Obstruction * 1/14 (7.14%)",
        "  Nausea * 1/14 (7.14%)",
        "  Stomatitis * 1/14 (7.14%)",
        "  Vomiting * 1/14 (7.14%)"
    ]
}